Држава: Аустралија
Језик: Енглески
Извор: Department of Health (Therapeutic Goods Administration)
Hepatitis a virus antigen; Salmonella typhi Vi polysaccharide
Sanofi-Aventis Australia Pty Ltd
Medicine Registered
VIVAXIM ® _Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about VIVAXIM ® It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines, including vaccines, have risks and benefits. Your doctor has weighed the risks of you having VIVAXIM ® against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT THIS VACCINE, ASK YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. WHAT VIVAXIM ® IS USED FOR VIVAXIM ® is a vaccine used to help prevent Typhoid fever and Hepatitis A disease in adults over the age of 16 years who are at risk of these diseases. _HOW IT WORKS_ VIVAXIM ® works by causing your body to produce its own protection against typhoid fever and hepatitis A infection. It does this by making substances called antibodies in the blood, which fight the typhoid bacteria and hepatitis A viruses. If a vaccinated person comes into contact with the typhoid or hepatitis A organisms, the body is usually ready to destroy them. Your body usually takes two weeks after vaccination to develop protection against typhoid fever and hepatitis A infection. Initial protection is provided by one dose of VIVAXIM ® . For long-term protection against hepatitis A virus a booster vaccination with an inactivated hepatitis A vaccine will be required 6 to 36 months after vaccination with VIVAXIM ® . The body does not develop long-term protection against typhoid fever and repeat vaccinations are required to maintain protection. Most people will produce enough antibodies against typhoid fever and hepatitis A infection. However, as with all vaccines, 100% protection cannot be guaranteed. The vaccine will not give you Typhoid fever or hepatitis A infection. The chance of a severe reaction from VIVAXIM ® is very small, but the risks from not being vac Прочитајте комплетан документ
sanofi pasteur VIVAXIM (_Salmonella typhi_ Vi polysaccharide & inactivated hepatitis A virus vaccine) PAGE 1 OF 11 AUSTRALIAN PRODUCT INFORMATION NAME OF THE MEDICINE VIVAXIM ® _Salmonella typhi_ Vi polysaccharide and inactivated hepatitis A virus antigen vaccine. DESCRIPTION VIVAXIM contains a sterile suspension of purified _Salmonella typhi _Vi polysaccharide and formaldehyde inactivated hepatitis A virus antigen (GBM strain) adsorbed onto aluminium hydroxide. VIVAXIM is presented in a dual-chamber by-pass syringe. The contents of both chambers are mixed immediately prior to injection by slowly pressing the plunger. Each 1 millilitre dose of mixed vaccine contains: ACTIVE INGREDIENTS: _Salmonella typhi _Vi polysaccharide (Ty 2 strain) 25 μg Hepatitis A virus antigen* 160 ELISA units** * GBM strain cultured on MRC-5 human diploid cells. MRC-5 is a cell line that was derived from human embryonic lung tissue in the 1960s. ** In the absence of an international standardised reference, the antigen content is expressed using an in-house reference. OTHER COMPONENTS: _Salmonella typhi _Vi polysaccharide typhoid vaccine components: Phosphate buffer solution containing: Sodium chloride 4.150 mg Sodium phosphate – dibasic dihydrate 0.065 mg Sodium phosphate – monobasic 0.023 mg Water for injections up to 0.5 mL Inactivated hepatitis A virus vaccine component: Aluminum hydroxide (quantity expressed as aluminium) 0.3 mg Phenoxyethanol (preservative) 2.5 µL Formaldehyde (preservative) 12.5 µg Medium 199 (Hanks)* up to 0.5 mL * Supplemented with polysorbate 80. Medium 199 (Hanks) without phenol red, is a complex mixture of amino acids including phenylalanine, mineral Прочитајте комплетан документ